Compare CVV & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | FEMY |
|---|---|---|
| Founded | 1982 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 21.9M |
| IPO Year | 2007 | 2021 |
| Metric | CVV | FEMY |
|---|---|---|
| Price | $5.55 | $0.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 165.4K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 17.86 | ★ 44.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,128,639.00 | $2,293,313.00 |
| Revenue This Year | N/A | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 96.27 | 40.77 |
| 52 Week Low | $2.75 | $0.31 |
| 52 Week High | $8.46 | $1.11 |
| Indicator | CVV | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 31.64 |
| Support Level | $3.08 | N/A |
| Resistance Level | $6.25 | $0.46 |
| Average True Range (ATR) | 0.63 | 0.04 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 14.47 | 2.84 |
CVD Equipment Corp is engaged in the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used to produce semiconductors and other electronic components. The company operates through the segments of CVD Equipment, CVD materials, and Stainless Design Concepts, MesoScribe. It generates maximum revenue from the CVD Equipment segment. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport, and similar equipment. Company operates in USA, North America, Europe, Middle East and Africa, and Asia-Pacific.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.